Zacks Research Has Negative Outlook for VRTX Q3 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Zacks Research dropped their Q3 2026 EPS estimates for shares of Vertex Pharmaceuticals in a report released on Monday, March 3rd. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will post earnings per share of $4.13 for the quarter, down from their previous estimate of $4.15. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ FY2027 earnings at $17.79 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and boosted their price target for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Wells Fargo & Company lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price target on the stock. in a research report on Thursday, January 30th. Morgan Stanley upped their price objective on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $506.70.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $485.72 on Wednesday. The business’s 50-day simple moving average is $446.68 and its 200 day simple moving average is $461.50. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The stock has a market cap of $124.73 billion, a price-to-earnings ratio of -220.78, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now owns 64,021 shares in the company, valued at approximately $29,438,776.43. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 1,084 shares of company stock valued at $505,512 in the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Dunhill Financial LLC raised its holdings in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the period. Brown Lisle Cummings Inc. bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Truvestments Capital LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $35,000. Finally, Sugar Maple Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $35,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.